ArticleFrontiers in pediatrics2026
MPC1 promotes the damage of human coronary endothelial cells in macrolide-resistant mycoplasma pneumoniae via inhibiting mitophagy.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: Human coronary endothelial cells (HCAECs) were co-cultured with MRMP. mRNA expression was calculated using quantitative reverse transcriptase PCR (qRT-PCR). Protein expression was detected using Western blot. Cytokine release was detected using enzyme-linked immunosorbent assay. The morphology of mitochondria was detected using transmission electron microscopy assay. The viability of HCAECs was determined using cell counting kit-8 assay. Cytotoxicity was determined using lactate dehydrogenase cytotoxicity assay. Cell death was analyzed using terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay. Results: We found that MRMP exposure mediated mitochondrial damage and pyroptosis of HCAECs. Moreover, MPC1 was overexpressed in HCAECs exposed to MRMP. Inhibition of MPC1 promoted mitophagy as well as suppressed the pyroptosis of HCAECs. However, blocking mitophagy signaling antagonized the effects of MPC1 deficiency, resulting in mitochondrial damage and pyroptosis of HCAECs. Conclusion: MPC1 promotes mitochondrial damage and pyroptosis of HCAECs in MRMP through inhibiting mitophagy. Therefore, targeting MPC1 may be a promising strategy for MRMP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.